Literature DB >> 27349252

GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Kathleen E O'Neill1, Suneeta Senapati2, Ivy Maina3, Clarisa Gracia2, Anuja Dokras2.   

Abstract

PURPOSE: The purpose of this study was to compare rates of ovarian hyperstimulation syndrome (OHSS) after using gonadotropin-releasing hormone agonists (GnRHa) alone and GnRHa in combination with low-dose human chorionic gonadotropin (hCG, dual trigger) for final oocyte maturation in women undergoing controlled ovarian hyperstimulation (COH).
METHODS: A retrospective cohort study was conducted at an academic center. Study population included 108 women who received GnRHa trigger and 66 women who received dual trigger (GnRHa + low-dose [1000 IU] hCG trigger). The main outcome measure was OHSS. Secondary outcomes included total oocyte yield and oocyte maturity.
RESULTS: The incidence of early OHSS was significantly higher after dual trigger than GnRHa trigger (8.6 vs 0 %). Moreover, four of the six patients that developed OHSS developed severe OHSS. Logistic modeling revealed that the combination of age, BMI, baseline AFC, and E2 >4000 pg/mL was predictive of OHSS with an area under the receiver operating characteristic curve of 0.84 and was superior to each factor alone. Adjusted analyses revealed that dual trigger was associated with a higher number of total oocytes (adjusted OR 1.27; 95 % confidence interval, 1.18, 1.38) and percentage of mature oocytes (AOR 1.10; 95 % confidence interval, 1.03, 1.17) obtained compared to GnRHa trigger alone.
CONCLUSIONS: Dual trigger for final oocyte maturation using GnRHa and low-dose hCG is associated with a significantly increased risk of severe OHSS compared to GnRH alone. However, dual trigger may be associated with a modest increase in oocyte yield, both in terms of number and maturity.

Entities:  

Keywords:  Dual trigger; GnRHa trigger; Low-dose hCG; OHSS; Oocyte maturity

Mesh:

Substances:

Year:  2016        PMID: 27349252      PMCID: PMC5010813          DOI: 10.1007/s10815-016-0755-8

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  61 in total

Review 1.  GnRH agonist for triggering of final oocyte maturation: time for a change of practice?

Authors:  P Humaidan; S Kol; E G Papanikolaou
Journal:  Hum Reprod Update       Date:  2011-03-30       Impact factor: 15.610

Review 2.  Prevention and treatment of ovarian hyperstimulation.

Authors:  J G Schenker
Journal:  Hum Reprod       Date:  1993-05       Impact factor: 6.918

3.  Initiation of periovulatory events in gonadotrophin-stimulated macaques with varying doses of recombinant human chorionic gonadotrophin.

Authors:  M B Zelinski-Wooten; J S Hutchison; I Trinchard-Lugan; D L Hess; D P Wolf; R L Stouffer
Journal:  Hum Reprod       Date:  1997-09       Impact factor: 6.918

4.  Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.

Authors:  María Cerrillo; Alberto Pacheco; Sara Rodríguez; Raúl Gómez; Francisco Delgado; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Fertil Steril       Date:  2011-01-26       Impact factor: 7.329

Review 5.  The ovarian hyperstimulation syndrome.

Authors:  J G Whelan; N F Vlahos
Journal:  Fertil Steril       Date:  2000-05       Impact factor: 7.329

6.  Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.

Authors:  Y Abramov; V Barak; B Nisman; J G Schenker
Journal:  Fertil Steril       Date:  1997-02       Impact factor: 7.329

7.  Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.

Authors:  David W Schmidt; Donald B Maier; John C Nulsen; Claudio A Benadiva
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

8.  Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome.

Authors:  R Agrawal; S L Tan; S Wild; P Sladkevicius; L Engmann; N Payne; J Bekir; S Campbell; G Conway; H Jacobs
Journal:  Fertil Steril       Date:  1999-02       Impact factor: 7.329

9.  Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist.

Authors:  J Itskovitz; R Boldes; J Levron; Y Erlik; L Kahana; J M Brandes
Journal:  Fertil Steril       Date:  1991-08       Impact factor: 7.329

10.  Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins.

Authors:  R V Haning; C W Austin; I H Carlson; D L Kuzma; S S Shapiro; W J Zweibel
Journal:  Fertil Steril       Date:  1983-07       Impact factor: 7.329

View more
  14 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

2.  Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Assist Reprod Genet       Date:  2016-07-22       Impact factor: 3.412

3.  Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation.

Authors:  Samantha B Schon; Maren Shapiro; Clarisa Gracia; Suneeta Senapati
Journal:  J Assist Reprod Genet       Date:  2017-06-27       Impact factor: 3.412

Review 4.  Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger).

Authors:  Sofia Andrade de Oliveira; Vinícius Fernando Calsavara; Gemma Castillón Cortés
Journal:  JBRA Assist Reprod       Date:  2016-12-01

Review 5.  The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.

Authors:  Neil Chappell; William E Gibbons
Journal:  Clin Exp Reprod Med       Date:  2017-06-30

6.  Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders

Authors:  Ahmet Eser; Belgin Devranoğlu; Evrim Bostancı Ergen; Çiğdem Yayla Abide
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-03-08

7.  Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.

Authors:  Miguel Russo; Kimberly Liu; Crystal Chan
Journal:  Reprod Biol Endocrinol       Date:  2020-06-05       Impact factor: 5.211

8.  GnRH agonist in association with hCG versus hCG alone for final oocyte maturation triggering in GnRH antagonist cycles.

Authors:  Condesmar M de Oliveira; Carlos A M de Oliveira; Larissa L Fonseca; Kelly R R de Souza; Moacir R M Radaelli
Journal:  JBRA Assist Reprod       Date:  2021-04-27

9.  Low dose hCG supplementation in a Gn-RH-agonist trigger protocol is associated with worse pregnancy outcomes: a retrospective cohort study.

Authors:  Maren Shapiro; Phillip Romanski; Ann Thomas; Andrea Lanes; Elena Yanushpolsky
Journal:  Fertil Res Pract       Date:  2021-05-28

10.  Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.

Authors:  L L Engmann; B S Maslow; L A Kaye; D W Griffin; A J DiLuigi; D W Schmidt; D R Grow; J C Nulsen; C A Benadiva
Journal:  J Ovarian Res       Date:  2019-01-26       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.